Table 2.
Clinical efficacy and improvements in CNS-related symptoms in the study population
| BM cohort (N = 12) N(%) |
LM cohort (N = 16) N(%) |
|
|---|---|---|
| Median follow up duration | ||
| Month (range) | 6.3 (1.5–15.1) | 7.8 (1.9–15.4) |
| Median iPFS, months (95%CI) | 3.6 (1.435–5.705) | 4.3 (2.094–6.486) |
| Median PFS, months (95%CI) | 2.3 (0.000–4.677) | 4.3 (2.094–6.486) |
| Overall best intracranial response | ||
| ORR | 2 (22.2) | – |
| DCR | 8 (88.9) | – |
| CR | 0 (0.0) | – |
| PR | 2 (22.2) | – |
| SD | 6 (66.7) | – |
| PD | 1 (11.1) | – |
| Not evaluable | 3 (25.0) | – |
| Overall best extracranial response | ||
| ORR | 1 (8.3) | 1 (6.3) |
| DCR | 4 (33.3) | 7 (43.8) |
| CR | 0 (0.0) | 0 (0.0) |
| PR | 1 (8.3) | 1 (6.3) |
| SD | 3 (25.0) | 6 (37.5) |
| PD | 4 (33.3) | 1 (6.3) |
| Not evaluable | 4 (33.3) | 8 (50.0) |
| Number of OS events (%) | 4 (33.3) | 7 (43.8) |
| Number of PFS events (%) | 12 (100.0) | 9 (56.3) |
| Number of iPFS events (%) | 10 (83.3) | 9 (56.3) |
| Improvement in CNS-related symptoms | ||
| Improvement | 3 (100.0) | 8 (53.3) |
| No improvement | 0 (0.0) | 4 (26.7) |
| Deterioration in symptoms | 0 (0.0) | 3 (20.0) |
The percentages might not equal 100% on account of rounding
n number, CNS central nervous system, iPFS intracranial progression-free survival, PFS progression-free survival, CR complete remission, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate (ORR = CR + PR), DCR disease control rate (DCR = CR + PR+ SD)